Globus Medical, Inc. (GMED) News
Track canonical SquawkNews coverage tagged to GMED, Globus Medical, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Prim Extends Distribution Contract With Globus Medical Until 2033
Prim SA BME:PRM
NEWS | Sep 23, 2026, 02:56 PM UTC
H
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it w
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance fol
EARNINGS | Sep 08, 2026, 04:05 PM UTC
L
Globus Medical gets CE Mark for Excelsius3D imaging system
Globus Medical announced CE Mark approval for its Excelsius3D™ imaging system.
EQUITY | Sep 03, 2026, 08:37 PM UTC
M
Globus Medical to acquire Higgs Boson Health
Globus Medical (GMED) announced an acquisition of Higgs Boson Health to transform the healthcare experience via AI-driven digital solutions.
MNA | Aug 26, 2026, 09:57 PM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
L
Globus Medical Raises FY2026 Adj EPS Guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B
Globus Medical (NYSE: GMED ) raises FY2026 Adj EPS guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180 billion-$3.220 billion vs $
EARNINGS | Aug 06, 2026, 08:32 PM UTC
L
ATEC Initiate with a Buy, GMED initiate with a Neutral @ UBS
ATEC Initiate with a Buy, GMED initiate with a Neutral @ UBS
EQUITY | Jul 28, 2026, 11:50 AM UTC
L
GMED Initiated Neutral W/$82.00 PT at UBS
GMED Initiated Neutral W/$82.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
EQUITY | Jul 21, 2026, 12:24 PM UTC
H
BMO Capital starts Globus Medical at Outperform on earnings power
As previously reported, BMO Capital initiated coverage of Globus Medical with an Outperform rating and $94 price target. The market continues to underappreciate the earnings power of the fully integrated platform, the an
EQUITY | Jul 08, 2026, 08:30 PM UTC
H
Globus Medical price target lowered to $80 from $95 at Stifel
Stifel analyst Thomas Stephan lowered the firm's price target on Globus Medical to $80 from $95 and keeps a Hold rating on the shares. 2026 revenue expectations are being lowered toward the low end of guidance due to wea
EARNINGS | Jul 08, 2026, 11:03 AM UTC